News
Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
1d
Discover Magazine on MSNOzempic and Other GLP-1 Side Effects May Outweigh the BenefitsGlucagon-like peptide-1 receptor agonists (GLP-1RA) drugs, such as Ozempic and Wegovy, are often referred to as "miracle ...
The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...
GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...
1d
CivicScience on MSNGLP-1 Trends by CivicScience: Access and Shortages, Desire for Customized Products, and Self-Care PreferencesThis is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...
Temperature-controlled packaging solutions provider Nordic Cold Chain Solutions has introduced what it claims to be the first cold chain packaging solution tailored for transporting glucagon-like ...
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...
Mouse livers were engineered via a one-time genome editing to secrete a GLP-1, cutting weight gain and improving glucose ...
Here’s a roundup of numbers from the last week of HR news — including the percentage of managers who use AI to help determine ...
The company’s new range promises to elevate nutritional support for consumers on weight management medications ...
DoseSpot, which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today the results of a new data analysis on 102, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results